News

Source: Fierce Biotech AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi. Apogee’s lead candidate is zumilokibart,…

Source: Fierce Biotech Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will give Jazz control of the brain cancer drug…

Source: FiercePharma The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger patient population as roughly 26 million in the U.S. have…

Source: FiercePharma With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion,…

Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation…

Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of…

Meet Rick Beck, a highly respected executive recruiter with a passion for connecting top talent with leading companies in the pharmaceutical, medical device, and biotechnology industries. With a nationwide reach, Rick and his team use a unique 48-point assessment…

Clichy, September 23, 2022 – L’Oréal signed an agreement to acquire Skinbetter Science, a physician-dispensed American skincare brand backed by cutting-edge, dermatological science, combining patented efficacious ingredients with luxurious sensorial textures….

Source: EPI Health The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN). Novan will host a conference call and webcast, today, March…

Source: GlobeNewswire Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today…